

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1548)**

## **UPDATE ON THE INVESTIGATION**

Reference is made to the announcements of GenScript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 21 September and 22 November 2020 (the “**Announcements**”). Unless the context requires otherwise, terms used in this announcement shall have the same meanings as defined in the Announcements.

The Board wishes to report on an update in connection with the Investigation pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board wishes to report that Dr. Zhang Fangliang (“**Dr. Zhang**”), the former chairman and chief executive officer of the Company and the former chairman of the board of directors and chief executive officer of Legend Biotech, was released on bail by the Authority on 9 February 2021.

At the time of this announcement, to the best of the Company’s knowledge, no formal charge has been made against Dr. Zhang.

As at the time of this announcement, to the best of the Company’s knowledge, no charges have been made or filed against any entity or individual.

To the best of the Company’s knowledge, there have been no other details released by the Authority as at the date of this announcement.

As at the date of this announcement, the Group’s business operations remain normal.

The Company has taken legal advice as appropriate. The Company will monitor this matter and will proactively assist the law enforcement authority with the Investigation, if required. The Company will make public announcement in a timely manner on any important development of the Investigation.

**Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.**

By Order of the Board  
**Genscript Biotech Corporation**  
**MENG Jiange**  
*Chairman and Executive Director*

Hong Kong, 9 February 2021

*As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.*

\* *For identification purposes only*